A Multicenter Study of the Clonal Structure and Resistance Mechanism of KPC-producing Escherichia Coli Isolates in Israel
Overview
Authors
Affiliations
Little is known about the molecular epidemiology of Klebsiella pneumoniae carbapenemase-producing Escherichia coli (KPCEC). We aimed to describe the clonal structure and resistance mechanisms of KPCEC in a multicenter study. The study included 88 isolates from four medical centres in Israel: Tel Aviv Medical Center (n = 17), Laniado Medical Center (n = 12), Sha'are-Zedek Medical Center (n = 38), and Rambam Medical Center (n = 21). Twelve (14%) KPCEC were from clinical sites and 86% from surveillance cultures. The clonal structure was studied by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) and was highly diverse, with 79 and 45 different PFGE types and STs, respectively. The most common clones were ST-131 and ST-410, identified in 21 isolates (23%). Dominant clonal complexes (CCs) were CC131 (n = 16), CC410 (n = 14), CC10 (n = 17), and CC-69 (n = 6). The blaKPC-2 and blaKPC-3 genes were identified in 68 and 20 isolates, respectively. All isolates were non-susceptible to ertapenem; 16 (18%) and 35 (40%) isolates were susceptible (minimal inhibitory concentration ≤1 mg/L) to imipenem and meropenem, respectively. Isolates were susceptible to colistin, amikacin, ciprofloxacin, gentamicin, and trimethoprim-sulfamethoxazole in 100%, 87%, 28%, 27%, and 21% of the cases, respectively. blaKPC-Harbouring plasmids from Tel Aviv Medical Center as well as from six CC-131 isolates from the other centres were studied by Inc and pMLST typing. Sixteen of the 20 blaKPC2-harbouring plasmids were of identical type, IncN-pMLST ST-15. In conclusion, the clonal structure of KPCEC in Israel is characterized by the predominance of known international extended-spectrum β-lactamase-producing clones and by high intra- and inter-institutional diversity. This suggests that in Israel, clonal spread does not play a major role in the dissemination of KPCEC.
sequence type 410 with carbapenemases: a paradigm shift within toward multidrug resistance.
Pitout J, Peirano G, Matsumura Y, DeVinney R, Chen L Antimicrob Agents Chemother. 2024; 68(2):e0133923.
PMID: 38193668 PMC: 10869336. DOI: 10.1128/aac.01339-23.
Lazarovits G, Gefen O, Cahanian N, Adler K, Fluss R, Levin-Reisman I Clin Infect Dis. 2022; 75(10):1706-1713.
PMID: 35451002 PMC: 10645045. DOI: 10.1093/cid/ciac281.
Piazza A, Principe L, Comandatore F, Perini M, Meroni E, Mattioni Marchetti V Antibiotics (Basel). 2021; 10(6).
PMID: 34203731 PMC: 8232337. DOI: 10.3390/antibiotics10060718.
Species Transferability of Carbapenemase-2 Isolated from a High-Risk Clone of ST410.
Lee M, Choi T J Microbiol Biotechnol. 2020; 30(7):974-981.
PMID: 32522962 PMC: 9728272. DOI: 10.4014/jmb.1912.12049.
Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.
Manges A, Geum H, Guo A, Edens T, Fibke C, Pitout J Clin Microbiol Rev. 2019; 32(3).
PMID: 31189557 PMC: 6589867. DOI: 10.1128/CMR.00135-18.